Introduction
Ellagitannins are polyphenolic natural products with a wide range of biological activities, including antioxidant, antivirus, and antitumor activities. This class of compounds may therefore be useful in medicinal applications. 1) Additionally, several researchers have expressed an interest in the structural diversity within this class of compounds with particular emphasis on those structures exhibiting axially chiral biaryl components.
2) Effective methods for constructing axially chiral biaryl moieties have been 
3
The synthetic strategy described here is based on the initial construction of a valoneoyl group with subsequent attachment to a suitable glucose core. Trimethyl octa-O-methyl valonate (1) , which has been frequently identified in structural determination of ellagitannins, 5) was chosen as the initial synthetic target. Despite being an important structural component of the ellagitannin family, an asymmetric synthesis of 1 has not previously been reported. 8) Axial chirality was generated using Bringmann's 'lactone concept,' which is an effective method for synthesizing axially chiral biaryl-type natural products.
9) It was thus expected that this technique would be applicable to the synthesis of hexadecamethyl derivatives of isorugosin B (2) 5d),5e) and rugosin B (3), 5f) which are the corresponding regioisomeric ellagitannins.
The current study demonstrates the first reported synthesis of valoneoyl-containing ellagitannins through the enantioselective construction of trimethyl octa-O-methyl valonate (1) and the syntheses of all-methylated versions of isorugosin B (2) and rugosin B (3).
10)

Results and Discussion
Enantioselective Synthesis of Trimethyl Octa-O-Methyl Valonate 1. The initial synthetic outline of
1 is depicted in Scheme 1. The target molecule 1 was synthesized from the six-membered ring lactone 4 using Bringmann's 'lactone concept' to forge the axially chiral biaryl components through a series of functional group manipulations. In this way, lactone 4 is a key intermediate in the synthesis. A Pdcatalyzed intramolecular biaryl coupling reaction 11) is presumably a useful method for the formation of 4, which requires ester 5 as a precursor. Ester 5 can be obtained by a simple esterification between the corresponding carboxylic acid 6 12) and phenol 7. Phenol 7 can be prepared by an Ullmann-type coupling 13) of phenol 8 14) and bromide 9.
15) SCHEME 1. Synthetic outline of 1. The synthesis of 1 began with the preparation of the biaryl ether 10 through an Ullmann condensation of phenol 8, 14) which was obtained from commercially available methyl gallate according to a previously reported method, and bromide 9 15) (Scheme 2). Deprotection under hydrogenolysis conditions provided phenol 7, which underwent esterification with carboxylic acid 6 12) using EDC to afford ester 5 as a precursor of the intramolecular biaryl coupling reaction. However, all attempts to prepare the coupling product 4 were unsuccessful. This result is similar to previous results, 16) in which the electronwithdrawing properties of the ester group adjacent to the reacting position interfered with the Pdmediated biaryl coupling reaction. SCHEME 2. Attempt to construct the six-membered ring lactone 4.
Accordingly, the ester group was converted to a carbinol or a protected carbinol, such as an acetoxymethyl or a siloxymethyl group. Converting the ester to an unprotected carbinol did not improve reactivity. In contrast, conversion to a protected carbinol provided the desired results; the best yields were obtained with the acetyl-protected carbinol. The synthesis of the six-membered lactone 14 is summarized in Scheme 3. Two ester groups in 10 were reduced with LiAlH 4 and acetylated to yield the bis-acetoxymethyl compound 11, which was debenzylated to form phenol 12. Phenol 12 was condensed with carboxylic acid 6 using the same conditions as those in Scheme 2 to yield the coupling precursor 13.
The intramolecular biaryl coupling reaction of 13 with Pd(OAc) 2 , Ph 3 P and NaOAc produced the desired lactone 14 in good yield. SCHEME 3. Construction of six-membered ring lactone 14.
In the next stage, Bringmann's lactone opening reaction was applied to 14 to construct the axially chiral biaryl components (Scheme 4). The asymmetric reduction of 14 with a borane-CBS reagent system 17) succeeded in generating the optically active biaryl compound 15 in an enantiomerically pure form. The phenolic hydroxy group was subsequently methylated, and successive reduction of the two acetoxy groups produced the triol 17. A final two-step oxidation of three hydroxy groups and methylation of the resulting carboxylic acids gave compound 1. The absolute configuration of the synthetic material was determined by comparing the sign of optical rotation with that in previously 6 reported data. 18) The stereoselectivity of the asymmetric reduction could be explained by the Bringmann's model. 9) The above procedure was successful in producing (S)-1. SCHEME 4. Synthesis of (S)-1. Syntheses of Methylated Ellagitannins. Given the success of the above synthesis, the strategy was expanded to produce the ellagitannin regioisomers, isorugosin B and rugosin B. As discussed above, this class of ellagitannins has not been previously synthesized because of difficulties inherent in the construction of the valoneoyl group on the sugar moiety. However, the above strategy enabled a smooth conversion of the axially chiral valoneoyl group into all-methylated versions of isorugosin B (2) and rugosin B (3).
The syntheses of 2 and 3 were relatively simple, as illustrated in Scheme 5. The most difficult step was the connection of the biaryl unit to the sugar moiety. This requires that two ester groups be formed in the final stage of the syntheses. In this context, the axially chiral biaryl compound 18 was the rational intermediate for regioselective esterification of glucose derivative 19. 19) Although 18 can be obtained by a method analogous to that described above, the three ester groups in the valoneoyl group must be distinguishable from each other. As depicted in Scheme 6, the synthesis started with the preparation of the biaryl ether by an Ullmann condensation between (siloxymethyl)phenol 20, which was obtained by LiAlH 4 reduction and TBS protection of 8, and the bromide 9. Aldehyde 21 was isolated in 9% yield along with many other undesired by-products. It is likely that compound 20 underwent thermolysis of its silyl group, with subsequent auto-oxidation, to afford the formyl compound 22 as a reactive species. Thus, it was considered that 22 would be a suitable synthetic precursor for the formation of the biaryl ether. Based on this, 22 was synthesized from 8 by LiAlH 4 reduction and Jones oxidation. The biaryl ether 21 was then obtained in good yield from the reaction of 22 and 9. Reduction of the formyl group and deprotection of the benzyl group provided the benzyl alcohol 23. Protection of the benzylic hydroxy group of 23 using a TBSCl-imidazole system succeeded in providing the desired phenol fragment 24. Phenol 24 was then coupled with carboxylic acid 6 to afford the ester 25. Ester 25 was then subjected to the intramolecular biaryl coupling reaction, using the same conditions as those in the previous scheme, to afford lactone 26.
The lactone opening reaction of 26 proceeded smoothly under Bringmann's conditions to generate the axially chiral biaryl compound 27 in high enantiomeric excess, which was methylated to afford the benzyl alcohol 28. The absolute configuration of the biaryl moiety was confirmed by a one-pot transformation of 28 to 17, and measurement of the optical rotation. 20) Finally, a two-step oxidation (PDC oxidation and Pinnick oxidation 21) ) of (S)-28 resulted in the optically active carboxylic acid (S)-18 as a key intermediate of the synthesis. SCHEME 6. Synthesis of key intermediate 18.
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With the mono carboxylic acid (S)-18 in hand, an eleven-membered ring system was formed via a double esterification reaction between 18 and a glucose derivative (Scheme 7). Glucose derivatives 29
and 32 were prepared from compound 19.
22) The first attachment of 18 to 29, followed by selective desilylation of the primary alcohol, yielded the desired alcohol 30 as a single diastereoisomer, which was then oxidized to the ring-closing precursor, carboxylic acid 31. The final manipulation of 31 consisted of removal of the TBS group with TBAF, and a subsequent intramolecular esterification under typical conditions to afford all-methylated isorugosin B (2). The moderate yield of this step may be due to the low reactivity of the secondary hydroxy group of the sugar. While the NMR spectrum of synthetic 2 was identical to that of the authentic chart, significant differences were observed regarding the sign of optical rotation. 23) This discrepancy was likely due to impurities in the natural sample, as evidenced by unidentified peaks in the authentic NMR chart.
The current investigation was concluded with the synthesis of 3, which is a regioisomer of 2. An esterification reaction between 18 and 32 with successive deprotection gave alcohol 33, which was then subjected to a two-step oxidation to yield the carboxylic acid 34. Finally, deprotection of the MOM group on the sugar moiety with aqueous HCl and successive esterification resulted in the synthesis of all-methylated rugosin B (3). The NMR spectrum and the optical rotation of synthetic 2 matched those of the reported data. 23) 9 SCHEME 7. Synthesis of 2 and 3.
Conclusions
An efficient strategy for the synthesis of valoneoyl-containing ellagitannins, which involved a Pdcatalyzed intramolecular biaryl coupling reaction, Bringmann's lactone opening reaction, and a two-step ester formation with the sugar core, was demonstrated. This process enabled syntheses of the valoneic acid derivative (1), and all-methylated versions of isorugosin B (2) and rugosin B (3). Based on these results, further syntheses of other natural ellagitannins, including isorugosin B, rugosin B, and oenothein B are underway.
Experimental Section
General Information
Melting points were measured using Yanagimoto micro melting point hot-plate and are uncorrected.
Optical rotations were determined on a JASCO P-1020 or -1030 digital polarimeter. IR spectra were recoded on a Jasco FTIR-350 spectrophotometer. NMR spectra were taken with Varian Unity INOVA AS600 (600 MHz), Varian VXR-500 (500 MHz), Mercury 300 (300 MHz) or JEOL α-400 (400 MHz) Solvents were dried using standard procedure. 2950, 2840, 1725, 1700, 1590, 1490, 1460, 1430, 1415, 1380, 1350, 1330, 1230, 1185, 1125, 1100, 1030, 990, 945, 840 52.3, 56.3, 61.3, 61.3, 61.5, 71.2, 108.3, 108.9, 109.6, 119.3, 127.5, 128.2, 128.7, 131.4, 136.4, 142.1, 143.9, 147.0, 147.3, 150.5, 153.1, 153.2, 165.0, 190.9 65.0, 71.0, 105.8, 106.3, 108.7, 119.4, 127.4, 128.0, 128.6, 136.5, 137.1, 137.6, 142.7, 147.1, 147.2, 150.1, 152.6, 152.9, 165.5 52.4, 56.3, 61.3, 61.5, 64.9, 104.4, 107.5, 108.8, 119.5, 134.8, 137.0, 142.2, 147.1, 147.3, 149.7, 150.3, 151.9, 165.4 20. 6 mmol), and imidazole (1.40 g, 20. 6 mmol) were added at room temperature. After stirring for 10 min under Ar atomosphere, the mixture was poured into H 2 O (100 mL) and extracted with CH 2 Cl 2 (100 12 mL×3). The combined organic layer was washed with brine (100 mL), dried over MgSO 4 , and filtrated.
Methyl 2-(3-benzyloxy-5-formyl-2-methoxyphenoxy)-3,4,5-trimethoxybenzoate (21).
The filtrate was evaporated, and the pale yellow residue (11.1 g) was purified by silica gel column chromatography (1 : 2 ; EtOAc : hexane), providing 24 (5.49 g, 95%) as a colorless oil: IR (neat) υ max 3440, 2960, 2860, 2360, 1730, 1720, 1600, 1505, 1495, 1460, 1430, 1415, 1350, 1220, 1120, 1080, 1040, 990, 840, 780 18.3, 25.9, 52.4, 56.4, 61.3, 61.4, 61.4, 64.4, 103.4, 106.0, 108.8, 119.6, 134.1, 137.5, 142.4, 147.3, 147.4, 149.5, 150.3, 151.8, 165.4 3020, 2940, 2860, 1730, 1590, 1460, 1430, 1340, 1230, 1200, 1170, 1125, 1105, 1080, 1040, 1000, 840, 670. 18.2, 25.9, 52.5, 56.4, 56.5, 61.0, 61.2, 61.3, 61.3, 61.5, 63.9, 84.9, 108.9, 109.6, 111.4, 113.0, 119.5, 129.9, 137.1, 13 139.4, 142.3, 144.1, 145.6, 147.2, 147.3, 150.4, 153.0, 153.5, 154.2, 164.6, 165.4 25.8, 52.3, 56.4, 56.5, 61.3, 61.4, 61.5, 61.5, 61.9, 64.0, 108.0, 109.0, 109.6, 110.2, 118.1, 119.4, 123.3, 134.7, 135.0, 142.3, 144.2, 147.2, 147.4, 148.4, 149.5, 150.5 
5-tert-
(S)-6-tert-Butyldimethylsilyloxymethyl-2-hydroxy-6'-hydroxymethyl-2',3,3'4'-tetramethoxy-4-(2,3,4-trimethoxy-6-methoxycarbonylphenoxy)-1,1'-biphenyl (27). To a solution of (S)-5,5-
Diphenyl-2-methyl-3,4-propano-1,3,2-oxazaborolidine (2.37 g, 8.55 mmol) in THF (50 mL), 1. 25.8, 52.3, 56.0, 56.4, 60.9, 61.1, 61.3, 61.3, 61.5, 62.8, 63.8, 105.3, 108.6, 108.9, 114.1, 119.6, 120.6, 134.3, 135.9, 136.1, 142.0, 142.5, 146.7, 147.3, 147.4, 150.4, 151.3, 151.6, 153.4, 165.5 25.8, 52.3, 56.0, 56.4, 60.7, 60.9, 61.1, 61.3, 61.3, 62.6, 63.9, 108.4, 108.8, 108.9, 119.5, 121.0, 121.1, 135.7, 135.8, 140.7, 141.5, 143.0, 147.2, 147.4, 150.2, 151.0, 151.2, 152.7, 153.4, 165.6 3010, 2940, 2860, 1710, 1680, 1590, 1480, 1460, 1430, 1415, 1350, 1320, 1230, 1120, 1090, 1000, 840, 670 18.1, 25.8, 52.3, 56.2, 56.4, 60.8, 61.2, 61.3, 61.4, 62.5, 105.1, 107.8, 108.9, 117.2, 119.5, 128.2, 129.8, 136.2, 140.3, 142.8, 147.3, 147.4, 147.8, 150.3, 151.3, 151.7, 153.4, 153.4, 165.5, 191.3; Anal.calculated 3010, 2940, 2860, 1720, 1595, 1480, 1460, 1430, 1420, 1400, 1350, 1320, 1230, 1120, 1085, 1035, 1000, 840, 670 7, -5.6, 18.2, 25.8, 52.3, 56.2, 56.3, 60.7, 61.0, 61.0, 61.0, 61.2, 61.3, 63.8, 108.6, 108.8, 109.5, 119.6, 121.8, 124.2, 127.0, 134.0, 141.0, 143.0, 145.9, 147.3, 147.4, 150.2, 151.3, 151.4, 152.7, 152.8, 165.8, 170.6 67 g ) was subjected to silica gel column chromatography (1 : 1 ; EtOAc : hexane), providing a mixture (1.47 g) of ester product and 29 as a colorless amorphous foam. The obtained mixture was directly dissolved in THF (7 mL) and H 2 O (14 mL), and then AcOH (42 mL) was added to the solution which was stirred at room temperature. After 9 h, the reaction mixture was extracted with Et 2 O (100 mL×3) and the combined organic layer was washed with sat. NaHCO 3 aq. (80 mL×3 17.9, 25.6, 52.2, 55.4, 56.1, 56.2, 56.3, 56.3, 60.8, 60.9, 60.9, 60.9, 61.0, 61.1, 61.2, 61.3, 63.5, 63.9, 69.9, 70.1, 72.9, 73.5, 96.7, 107.0, 107.2, 108.8, 109.3, 110.9, 119.5, 123.3, 124.1, 124.9, 125.9, 126.1, 134.9, 141.7, 142.6, 142.6, 143.1, 146.2, 147.3, 147.4, 150.2, 151.1, 152.0, 152.6, 152.9, 153.0, 153.1, 165.8, 165.8, 165.9, 166.6 3020, 2940, 1720, 1685, 1590, 1460, 1420, 1340, 1230, 1175, 1130, 1090, 1035, 1000, 840, 670 of ABX, J = 1.6, 11.6 Hz, 4.92 (1H, dd, J = 3.6, 10.4 Hz, 5.11 (1H, d, J = 3.6 Hz, , 5.82 (1H, dd, J = 8.4, 10.4 Hz, 6.93 (1H, s, 7.17 (2H, s, 7.19 (2H, s, , 7.29 (1H, s, 7.46 (1H, s, 9.46 (1H, s, CHO) , glu-4-, 5-, and 6'-H overlapped with OMe signals; 13 C-NMR (100 MHz, CDCl 3 ) δ - 4.5, 17.9, 25.6, 52.3, 55.4, 56.2, 56.3, 56.3, 56.4, 60.7, 61.0, 61.0, 61.0, 61.2, 61.2, 61.2, 61.4, 63.6, 70.0, 70.1, 73.0, 73.6, 96.7, 107.0, 107.2, 108.5, 109.1, 109.5, 119.4, 123.4, 124.2, 124.9, 126.0, 129.4, 129.6, 142.6, 142.6, 146.1, 147.2, 147.5, 147.5, 150.6, 151.5, 152.4, 153.1, 165.3, 165.5, 165.8, 165.9, 190.5.; 3020, 2940, 2360, 1720, 1590, 1460, 1420, 1340, 1230, 1130, 1085, 675, 665 4.10 (1H, dd, B of ABX, J = 5.2, 11.6 Hz, 4.63 (1H, dd, A of ABX, J = 1.2, 11.6 Hz, 4.91 (1H, dd, J = 3.6, 10.4 Hz, 5.09 (1H, d, J = 3.6 Hz, 5.82 (1H, dd, J = 8.4, 10.4 Hz, 6.98 (1H, s, 7.17 (2H, s, 7.19 (2H, s, 7.27 (1H, s,  Valoneoyl-H), 7.36 (1H, s, , glu-4-and 5-H overlapped with OMe signals; 13 C-NMR (100 MHz, CDCl 3 ) δ - 4.5, -4.0, 18.0, 25.6, 52.3, 55.3, 55.9, 56.2, 56.3, 56.3, 60.6, 60.8, 60.9, 61.0, 61.0, 61.0, 61.2, 61.3, 63.4, 70.0, 70.2, 73.0, 73.6, 96.7, 107.1, 107.2, 108.9, 108.9, 112.7, 119.4, 124.2, 124.5, 124.6, 125.0, 127.1, 127.1, 142.6, 142.6, 142.7, 146.0, 146.2, 147.2, 147.4, 150.4, 151.5, 151.7, 152.0, 152.3, 153.1, 165.7, 165.8, 165.9, 166.0 52.4, 55.9, 56.4, 56.5, 56.5, 56.8, 60.6, 60.7, 60.9, 61.1, 61.1, 61.2, 61.3, 61.6, 64.0, 67.5, 71.0, 72.2, 73.6, 98.4, 107.0, 108.0, 108.1, 109.1, 109.7, 120.5, 123.0, 124.1, 125.0, 125.1, 128.9, 129.9, 142.6, 143.8, 144.0, 145.1, 145.2, 148.0, 148.2, 151.7, 153.5, 153.6, 153.9, 154.2, 154.3, 154.3, 165.8, 165.9, 166.3, 167.6, 168.2 3030, 3010, 2940, 2840, 1725, 1590, 1505, 1460, 1420, 1340, 1235, 1175, 1130, 1085, 1035, 1000, 920, 860, 670 7, 18.0, 25.7, 52.2, 55.4, 55.6, 55.7, 56.2, 56.3, 56.3, 60.5, 60.7, 60.9, 61.0, 61.0, 61.0, 61.2, 61.4, 62.1, 64.9, 68.4, 68.4, 71.5, 72.7, 97.0, 97.1, 107.0, 107.0, 107.2, 108.9, 109.3, 119.7, 121.1, 124.3, 124.5, 124.5, 125.6, 136.0, 140.1, 142.5, 142.6, 143.2, 146.0, 147.4, 147.5, 150.3, 151.0, 151.6, 152.5, 152.9, 153.1, 153.1, 165.4, 165.6, 165.7, 165.8 3520, 3030, 3010, 2940, 2840, 1720, 1590, 1505, 1460, 1420, 1340, 1230, 1175, 1130, 1085, 1035, 1000, 920, 865, 670 1, 55.6, 55.6, 56.0, 56.2, 56.2, 56.3,60.4, 60.6, 60.9, 60.9, 61.0, 61.2, 61.4, 63.0, 65.4, 68.5, 68.6, 71.1, 72.5, 96.8, 97.0, 107.0, 107.2, 108.8, 108.9, 109.9, 119.6, 123.0, 124.0, 124.0, 124.7, 125.3, 134.6, 141.0, 142.7, 142.8, 143.0, 146.2, 147.3, 147.5, 150.2, 151.3, 151.6, 152.5, 152.8, 153.1, 165.2, 165.6, 165.8, 166.1 
Methyl
4-O-tert-butyldimethylsilyl-6-O-[(S)-2-{6-hydroxymethyl-
Methyl 4-O-tert-butyldimethylsilyl-6-O-[(S)-2-{6-carboxy-
